SecBot SecBot

BDTX

Black Diamond Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001701541 Biotech & Drug Discovery
$1.69 −0.19 (−10.11%)
Oct 26 4:00 PM ET · prev $1.88
Market cap
$119.5M
Micro cap
Median target
$10.00
+492% · range $8.00–14.00
Next earnings
Nov 9
in 14 days · EPS est. −$0.06
1 year
−57.2%
from $3.95 · Oct 27
30 days
−7.7%
from $1.83
52-week range
$1.61–4.87
−65% from high · low Jun 22
Avg volume 20D
848.2K
Oct 21 spike 2.36M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·Next Earnings date, Nov 9, 2026
Strongest NEUTRAL Black Diamond Therapeutics reported Q2 2026 results with a net loss of -$0.17 per share, slightly narrower…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 17 added (0 new), 11 trimmed or exited.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.055 → −$0.055 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    14% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED3,917,088$7.2M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED1,218,171$2.3M
STATE STREET CORPDOUBLED525,013$971.3K
BANK OF AMERICA CORP /DE/DOUBLED413,516$765.0K
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED407,074$753.1K
Bank of New York Mellon CorpADD318,763$589.7K
JANE STREET GROUP, LLCDOUBLED289,712$536.0K
O'SHAUGHNESSY ASSET MANAGEMENT, LLCADD288,871$534.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Apr 2026
12-month targets · 7 analysts

Price is below the lowest target. Median implies +492%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Apr 29, 2026BTIG
MAINTAIN
MAINTAINBuy
Mar 17, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Jan 16, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Dec 4, 2025Guggenheim
DOWNGRADE
DOWNGRADENeutral
Oct 1, 2025Freedom Broker
INITIATE
INITIATEBuy
Sep 4, 2025Guggenheim
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 18, 2026
Raman Prakash
Director
AWARD$13.1K
Sep 18, 2026
Behbahani Ali
Director
AWARD$14.9K
Jun 26, 2026
Dhingra Kapil
Director
AWARD40,000 sh
Jun 26, 2026
Campbell Shannon
Director
AWARD40,000 sh
Jun 26, 2026
Menzel Garry E
Director
AWARD40,000 sh
Jun 26, 2026
Raman Prakash
Director
AWARD40,000 sh
Jun 26, 2026
Kulkarni Samarth
Director
AWARD40,000 sh
Jun 26, 2026
Behbahani Ali
Director
AWARD40,000 sh

Earnings setup

Estimates
Nov 9
reports in 14 days
−$0.06
EPS estimate, this quarter
0%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.06-$0.24–$0.62+8.3%$6.3M
Next Q-$0.20-$0.30–-$0.14+7.9%$0.00
Current FY-$0.57-$0.75–-$0.01+10.3%$6.3M
Next FY-$1.00-$1.75–-$0.52+13.9%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 18, 2026 Insider
Raman Prakash was granted 6,801 shares
Director @ $1.93 ($13.1K)
Sep 18, 2026 Insider
Behbahani Ali was granted 7,707 shares
Director @ $1.93 ($14.9K)
Aug 15, 2026 SEC
Eight institutional investors, led by BlackRock, State Street, and Geode, collectively doubled or added to their BDTX…
INST-CLUSTER — Impact 4/10
Aug 14, 2026 Short interest report
Short Interest: BDTX up 6% to 6.2M shares
Settlement 2026-08-14 | Days to cover: 10.36 | ≈10.77% of shares outstanding (est.)
Aug 5, 2026 SEC
Black Diamond Therapeutics reported Q2 2026 results with a net loss of -$0.17 per share, slightly narrower than the…
8-K — Impact 5/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
3,917,088 shares ($7.2M)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — DOUBLED
1,218,171 shares ($2.3M)
Jun 26, 2026 Insider
Dhingra Kapil was granted 40,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
BDTX Q3 2026 Earnings Scheduled — 2026-11-09
Recent
Aug 14, 2026
Short interest
Short Interest: BDTX up 6% to 6.2M shares
Settlement 2026-08-14 | Days to cover: 10.36 | ≈10.77% of shares outstanding (est.)
Aug 6, 2026
Earnings date
BDTX Q2 2026 Earnings Scheduled — 2026-08-06
Aug 5, 2026
Earnings
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing…
Aug 5, 2026
Earnings date
BDTX Q2 2026 Earnings Scheduled — 2026-08-05
Jul 15, 2026
Short interest
Short Interest: BDTX up 30% to 5.9M shares
Settlement 2026-07-15 | Days to cover: 3.73 | ≈10.21% of shares outstanding (est.)

SecBot reports

4 filings · 3 press releases · 1 bullish · 0 bearish · 3 neutral
All BDTX filing & press-release reports (7)